Lipid-based oil-filled nanoparticles (NPs) with a high concentration of surface-chelated nickel (Ni-NPs) were successfully prepared using a Brij 78-NTA-Ni conjugate synthesized with Brij 78 (Polyoxyethylene (20) stearyl ether) and nitrilotriacetic acid (NTA). The facile incorporation of the Brij 78-NTA-Ni conjugate into the NP formulation allowed up to 90% Ni incorporation, which was a significant improvement over the previously used standard agent DOGS-NTA-Ni which led to~6% Ni incorporation. The Ni-NPs were targeted to the highly epidermal growth factor receptor (EGFR)-overexpressing epidermoid carcinoma cells A431. This was accomplished using a novel high affinity histidine × 6-tagged EGFR-binding Z domain (heptameric Z EGFR domain). In vitro cell uptake studies showed enhanced internalization (up to 90%) of the targeted NiNPs in A431 cells with only ≤ 10% internalization of the untargeted Ni-NPs. ICP-MS analysis used to quantify the amount of Ni in the cells were in close agreement with flow cytometry studies, which showed a dose dependent increase in the amount of Ni with the targeted Ni-NPs. Cell uptake competition studies showed that internalization of the targeted Ni-NPs within the cells was competed off with free heptameric Z EGFR domain at concentrations of 8.75 ng/mL or higher. In vivo studies were carried out in nude mice bearing A431 tumors to determine the biodistribution and intracellular delivery. Near Infrared (NIR) optical imaging studies using Alexa750-labeled heptameric Z EGFR domain showed localization of 19% of the total detected fluorescence intensity in the tumor tissue, 28% in the liver and 42% in the kidneys 16 h post i.v. injection. ICP-MS analysis showed almost a two-fold increase in the amount of intracellular Ni with the targeted Ni-NPs. These new Ni-NPs could be a very useful tool for targeting and drug delivery to a wide range of EGFR positive cancers.
Introduction
One of the major requirements for a successful cancer therapeutic is the ability to selectively kill cancer cells with minimal damage to healthy tissue. Selective delivery of chemotherapeutics to cancer cells is an approach known as molecular targeted therapy. This technique is currently combined with chemotherapy and has the potential to replace it in the future [1] . The principle behind targeted therapy is to utilize molecules that interfere with the development and growth of cancer. Among these molecules, the human epidermal growth factor receptor (EGFR) has emerged as an attractive target for cancer therapy. The EGFR is a transmembrane tyrosine kinase receptor that regulates important cellular processes such as cell proliferation, apoptosis, differentiation and migration [2] . Overexpression of EGFR has been detected in a wide range of cancers including breast, ovarian, bladder, head and neck, glioma, pancreatic, kidney, lung and prostate, making it an attractive target for both therapeutic and diagnostic applications [3] [4] [5] . In the past decade, several EGFRtargeted anticancer therapeutics have been developed using either monoclonal antibodies (MAbs; cetuximab [6] , panitumumab [7] ) or tyrosine kinase inhibitors (TKIs; gefitinib [8] , erlotinib [9] , lapatinib [10] ) to block uncontrolled EGFR-mediated signaling [11] [12] [13] . More recently, a new class of affinity proteins known as affibody molecules has been introduced as an alternative approach to antibodies for EGFR-targeted systems [14, 15] . Affibodies are composed of 58 amino acid residues bundled in a three-helix scaffold, a structure derived from the Z-domain of staphylococcal protein A [16] . Additionally, affibody molecules are small (~7 kDa) and are easy to produce by recombinant production in bacteria or by chemical synthesis [17] . Moreover, these proteins have a very high affinity for different receptors including EGFR, HER2, HER3 and HER4 [18, 19] . Affibody proteins have been extensively investigated as in vivo imaging agents because of their relatively small size, their ability to exhibit fast tumor targeting, high tumor uptake, and quick clearance from normal tissue [20] [21] [22] . In addition, their high binding affinity to EGFR makes them a very appealing targeting ligand for the delivery of therapeutic agents to a wide range of EGFR-overexpressing cancer cells [23] .
To further enhance the binding efficiency, Liu et al. generated a heptameric EGFR-binding targeting ligand, by fusing a heptamerization domain with an EGFR-binding Z domain. The resulting heptameric targeting ligand is highly stable, can withstand SDS denaturing and binds to EGFR-expressing cancer cells with a significantly improved binding affinity. In vitro cell binding studies showed that as low as 0.1 nM of heptameric Z EGFR (125 kDa) bound to EGFR-positive A431 cells tightly and specifically, whereas more than 100 nM monomeric Z EGFR (18 kDa) was required to achieve similar results (unpublished results). The targeting ligand can be terminated with a histidine × 6-tag for site-specific attachment to various drug delivery systems such as liposomes and nanoparticles via his-tag-Ni affinity binding [24] . This approach has several advantages over the use of covalent linkages including, facile attachment, mild conditions and the ability to achieve site specific and oriented attachment and high coupling efficiencies [25] [26] [27] .
In the present studies, the surface of Ni-loaded NPs was decorated with a his × 6-tagged heptameric Z EGFR domain to target EGFRoverexpressing human epidermoid carcinoma A431 cells. In order to achieve tight association between the his × 6-tagged protein and the surface of the NPs, two different NTA-derivatized Brij surfactants (Brij 78-NTA and Brij 700-NTA) were synthesized and then used to prepare the lipid-based NPs. The synthesis of the new conjugates was simple and high yielding. Using these new conjugates, a significant increase (>10-fold) in Ni incorporation was achieved compared to previous results using the commercially available DOGS-NTA-Ni [28] . More importantly, the delivery of the EGFR-targeted Ni-NPs using the novel his × 6-tagged heptameric Z EGFR domain was accomplished in vitro and in vivo in A431 cancer cells. Combined, these results show a great potential for the novel heptameric Z EGFR domain as a targeting ligand to facilitate the delivery and accumulation of nanocarriers to various EGFR overexpressing tumor tissues. To our knowledge, this is the first report on the development of Ni-NPs using Brij 78-NTA-Ni conjugate and targeting Ni-NPs to EGFRoverexpressing cells using a novel heptameric Z EGFR domain.
Materials and methods

Materials
Chemicals
Polyoxyethylene (20) stearyl ether (Brij 78) was purchased from Uniqema (Wilmington, DE). D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) was purchased from Eastman Chemicals (Kingsport, TN). Miglyol 812 is a mixed caprylic (C 8:0 ) and capric (C 10:0 ) fatty acid triglyceride and was purchased from Sasol (Witten, Germany). TEMPO free radical (98%), iodobenzene diacetate (98%), N-hydroxysuccinimide (NHS) and nitrilotriacetic acid (NTA, 97 + %) were purchased from Sigma Aldrich (Milwaukee, MI). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 98+%) was purchased from Alfa Aesar (Ward Hill, MA). Nickel chloride hexahydrate was purchased from Fisher Scientific (City, State). Acetonitrile (CH 3 N), dichloromethane (CH 2 Cl 2 ), tetrahydrofuran (THF), ethanol (EtOH), and diethyl ether were purchased from Fisher Scientific.
Cells
A431 epidermoid carcinoma cells (American Type Culture Collection, Rockville, Maryland) were used as a model cell for their very high levels of epidermal growth factor receptor (EGFR) expression. Prior to cell uptake studies, A431 cells were cultured in Dulbecco's Modified Eagle Medium, high glucose (DMEM, Invitrogen™, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Mediatech Inc., Manassas, VA, USA) and 1% penicillin streptomycin solution (Pen Strep, Invitrogen™, Grand Island, NY, USA) at 37°C and 5% CO 2 .
Analysis
Optical microscopy analysis of cells was carried out using a Zeiss Invertoskop 40C Optical Microscope. Cells (10,000 per sample) were analyzed by flow cytometry (CyAn ADP, Dako), for green and red fluorescence. In vivo fluorescence imaging studies were carried out using the IVIS® Spectrum (Caliper Life Sciences) with an epiillumination (from the top) capability to illuminate in vivo fluorescent sources. .00 L/min, auxiliary flow 1.80 L/min, sheath gas flow 0.18 L/min and sampling depth 7.5 mm) were used. All solutions were prepared using 18 MΩ de-ionized water (lab supply) and trace metal grade Nitric Acid (Thermo Fisher Scientific Inc.). Instrument conditions were optimized using the auto-optimization feature of this instrument. Samples were introduced while setting the peristaltic pump at 3 rpm. The spray chamber was cooled to 3°C. Standards were prepared using ICP standards purchased from Inorganic Ventures, Christiansburg, VA. In all measurements, a 5 ppb solution of Indium was used as internal standard and mixed online with each sample through a tee. Ions In115 (internal standard), and 60 Ni were monitored in a peak hopping mode, using 50,000 μs as dwell time, and measuring 5 replicates of an average of 20 data points. This gave a scan time of 359 ms and replicate time of 7.17 s. The Ni standard curve included 9 to 13 concentration levels in the range of 0.1 to 500 ppb. The standard data set was fitted to a linear curve. The coefficient of correlation was 0.999 or higher in each of the several data sets. Percent Error in calculated concentrations was 11% or lower (in most cases it was less than 5%). The blank equivalent was less than 0.1 ppb. Only the test data greater than three times the blank equivalent (i.e. 0.3 ppb) were accepted as valid measurement. During the analysis of each test sample, a reference sample was used for validation and comparison of the test results. For quantitation of Ni in the NPs, preparation included removing the water from the NPs and re-suspending them in 2% HNO 3 solution. Cell samples with internalized Ni, from in vitro flow cytometry studies, involved taking a 0.5 mL of each cell sample and diluting it with 2% HNO 3 to a total volume of 3.0 mL. In the case of in vivo studies, tumor cells were extracted from homogenized tumors, using a digestion mixture (described in Section 2.2.6.1). The final cell pellet from this step was re-suspended in 2% HNO 3 to a total volume of 3.0 mL for analysis by ICP-MS. General procedure for the preparation of Ni-NPs using Brij 700-NTA-Ni. Nanoparticles were prepared from warm oil/water (o/w) microemulsion precursors following a previously reported procedure [29] . In the optimized formulation, Brij 78 (2.9 mg), TPGS (1.5 mg), Miglyol 812 (2.5 mg), and Brij 700-NTA-Ni (0.6 mg, 8 wt.%) were weighed into a 7 mL glass vial and heated in a water bath to 65°C to melt and blend the excipients. A small amount of ethanol (100 μL) was added to the melted excipients and the solution was swirled to help form a homogenous mixture. The ethanol was removed completely using a stream of nitrogen and the vial was transferred to a water bath at 65°C. One (1) mL of filtered and deionized (D.I.) water pre-heated at 65°C was added into the mixture of melted oil and surfactants, and the solution was stirred for 30 min at 65°C then cooled to room temperature.
2.2.2.2.
General procedure for the preparation of Ni-NPs using Brij 78-NTA-Ni. Nanoparticles were prepared from warm o/w microemulsion precursors as described above with some modification. In the optimized formulation, Brij 78 (0.7 mg), Brij 78-NTA-Ni (2.8 mg), TPGS (1.5 mg), and Miglyol 812 (2.5 mg) were weighed into a 7 mL glass vial and heated in a water bath to 65°C to melt and blend the excipients. A small amount of ethanol (100 μL) was added to the melted excipients and the solution was swirled to help form a homogenous mixture. The ethanol was removed completely using a stream of nitrogen and the vial was transferred to a water bath at 65°C. One (1) mL of filtered and deionized (D.I.) water pre-heated at 65°C was added into the mixture of melted oil and surfactants, and the solution was stirred for 30 min at 65°C then cooled to room temperature.
Optimization of histidine × 6-tagged green fluorescent protein (his-tag GFP) binding to Ni-NPs
Briefly, 500 μL of Ni-NPs was passed down a Sepharose CL-4B size exclusion chromatography (SEC) column (15 × 100 mm) column using PBS, pH 7.4 as a mobile phase. Fractions (1 mL) were collected and those containing NPs (as determined by dynamic light scattering measurement of particle size) were combined and used for binding his × 6-tagged GFP. Binding studies of his × 6-tagged GFP to Ni-NPs prepared with Brij 700-NTA-Ni were carried out using optimal binding conditions at a ratio of 0.0045 w/w his × 6-tagged GFP to Ni-NPs. The Ni-NPs were incubated with the corresponding amount of his × 6-tagged GFP in PBS, pH 7.4 at 4°C overnight. Free his × 6-tagged GFP was removed by a Sepharose CL-4B SEC column (15 × 70 mm) with PBS, pH 7.4 as the mobile phase. Fractions 1-24 (1 mL) were collected and analyzed by fluorescence spectroscopy to determine the percent of his × 6-tagged GFP bound to the Ni-NPs. The fluorescence was measured using a BioTek Synergy 2 Fluorescence Spectrometer (Winooski, VT) with excitation and emission wavelengths set at 494 and 518 nm, respectively.
Optimization of his × 6-tagged heptameric Z EGFR domain binding to
Ni-NPs
The Ni-NPs prepared with Brij 78-NTA-Ni were purified as described above and incubated with FITC-labeled heptameric Z EGFR domain at 2.5, 3.5, 5.0, 10 and 15 μg ligand/1500 μg Ni-NPs to determine the optimal binding conditions. Unbound targeting ligand was separated by SEC column using PBS, pH 7.4 as the mobile phase. Fractions 1-24 (1 mL) were collected and analyzed by fluorescence spectroscopy to determine the percent of his × 6-tagged FITC-labeled heptameric Z EGFR domain bound to the Ni-NPs. The fluorescence
was measured with excitation and emission wavelengths set at 494 and 516 nm, respectively.
In vitro cell uptake studies
The EGFR-overexpressing A431 cell line was used to investigate the uptake of EGFR-targeted Ni-NPs. A431 cells (passage 3) were cultured under standard conditions (37°C, 95% relative humidity, 5% CO 2 in Dulbecco's Modified Eagle Medium, high glucose (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin). For cell uptake experiments, the confluent cells were trypsinized and centrifuged using a Beckman Coulter, Allegra™ X-12R Centrifuge at 900 rpm for 5 min. The resulting cell pellet was re-suspended in the required amount of complete medium (DMEM) to achieve a cell-plating density of 20,000 cells per mL of medium. The cells were plated into 24-well tissue culture flat bottom plates (Corning/Costar 3526) and allowed to incubate overnight to about 40-50% confluency. The following day, untargeted and EGFR-targeted Ni-NPs were diluted in complete medium to obtain a final assay concentration of 1, 5, and 15 μg/mL. NPs (300 μL) were then incubated with cells over a time course ranging from 15 min to 4 h (37°C, 5% CO 2 ). After cell/NPs incubation, the cells were washed with 1× Dulbecco's Phosphate Buffered Saline solution (D-PBS) and detached by trypsinization (300 μL/well). Cells were resuspended in a 1:1 solution of 0.4% trypan blue (TB) solution in 1× D-PBS containing 10% FBS (500 μL/well; total sample volume 800 μL) and transferred to a 5 mL Falcon (352063) polypropylene round-bottom tube. This assay relies on the observation that the FITC-label of noninternalized particles acquires red fluorescence while losing its green fluorescence when incubated with the vital dye TB. Internalized particles on the other hand will fluoresce green [30] . Cells (10,000 per sample) were analyzed by flow cytometry (CyAn ADP, Dako), for green and red fluorescence.
In vivo studies
Female nude athymic (nu/nu) mice, 4 to 6 weeks (Harlan Laboratories), were housed in a pathogen-free room. All experiments involving the mice were carried out with an approved protocol by the University of North Carolina Animal Care and Use Committee. The mice were injected s.c. in the right flank region with 2 × 10 6 A431 cells suspended in DMEM. Tumors were measured in two perpendicular dimensions, and tumor volume was calculated using the formula
, where L and W are the longest and shortest diameters, respectively. When the tumors reached volumes between 300 and 500 mm 3 , the mice were randomly divided into three groups, a naïve group, a group injected with untargeted Ni-NPs and a third group injected with EGFR-targeted Ni-NPs using his × 6-tagged, Alexa750-labeled heptameric Z EGFR domain. Mice were injected with Ni-NPs in 200 μL of isotonic saline solutions via intravenous (i.v.) injection. homogenates were quantified by ICP-MS analysis. The mice were euthanized and the tumors were harvested and transferred to a solution of phosphate buffered saline (PBS, 5 mL) containing Fungizone (0.01%) and Penstrep (0.01%). The tumors were then transferred to a 50 mL Falcon tube containing 5 mL of complete DMEM, and homogenized using a Tissue Tearor™ (Biospec products, Inc.) homogenizer.
To dissociate single cells from tumor fragments, 20 mL of tumor digestion enzyme mixture (Hyaluronidase, Type V; Collagenase, type IV and DNase, Type IV, Sigma Aldrich) was added to the medium containing the cell homogenate, and the solution was mixed thoroughly followed by incubation for 3 h at 37°C with periodical mixing every 10-15 min. The cell homogenate solution was passed first, through a 70 μm sterile mesh filter, and a second time through a 40 μm sterile filter to ensure removal of any large undigested tumor fragments. The filtrate was centrifuged (Thermo IEC CL40R centrifuge) at 1100 rpm for 5 min. The resulting cell pellet was re-suspended in 9 mL of 1 × Osmotic Lysis Buffer for 30 s with continuous mixing to remove any red blood cells (RBC) contaminant. The cell suspension was centrifuged at 1100 rpm for 5 min, and the resulting cell pellet was resuspended in lysis buffer for 15 min at room temperature. Finally, the cell suspension was centrifuged at 1100 rpm for 5 min, and the resulting cell pellet was rinsed twice with Hank's buffer salt solution (HBSS, 5 mL). The cell pellet was re-suspended in HBSS (0.5 mL) and 2% nitric acid (2.5 mL) for ICP-MS analysis to quantify intracellular Ni accumulation within the tumor homogenate. 2% nitric acid was used for digestion and solubility purposes for ICP-MS analysis.
2.2.6.2. In vivo optical imaging. Fluorescence imaging studies were carried out 16 h post i.v. injection, using the IVIS® Spectrum (Caliper Life Sciences) with an epi-illumination (from the top) capability to illuminate in vivo fluorescent sources. Two weeks prior to i.v. injection, the mice were kept under alfalfa-free diet to minimize background fluorescence from the food. The heptameric Z EGFR domain was labeled with Alexa750 and conjugated to the Ni-NPs via non-covalent Ni-his × 6-tag affinity binding. The mice were anesthetized using isoflurane and transferred to the IVIS instrument to collect full body images (Ex. 745 nm and Em. 800 nm). The mice were given an overdose of ketamine and domitor to deeply anesthetize them prior to cardiac puncture to collect blood, and a cervical dislocation was then performed to euthanize the mice. The organs/tumors were harvested and transferred to 12-well plates and imaged using IVIS at 30 s scanning time.
Tumors and organs were weighed and percent fluorescence was qualitatively evaluated based on the total fluorescence detected from all organs, tumors and blood.
Scheme 1. Synthesis of Brij 700-NTA-Ni conjugate.
Statistical analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA) followed by pair-wise comparisons using Tukey's multiple comparison test using GraphPad Prism Software (©1992-2007 GraphPad Prism Software, Inc). Results were considered significant at 95% confidence interval (p b 0.05).
Results and discussion
Synthesis
Brij 700-NTA-Ni and Brij 78-NTA-Ni conjugates were prepared using the same synthetic strategy. For Brij 700-NTA-Ni, this was accomplished by first converting the terminal hydroxyl group of polyoxyl 100-stearyl ether (Brij 700) to a carboxylic acid group using the TEMPO-mediated oxidation [31] . The carboxylic acid derivative (2) of Brij 700 was subsequently reacted with excess N-hydroxysuccinimide (NHS) and 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The resulting NHS-active ester of Brij 700-acid (3) was subsequently reacted with nitrilotriacetic acid (NTA) to give Brij 700-NTA conjugate. The chelation of nickel to Brij 700-NTA (4) was carried out using excess NiCl 2 .6-H 2 O to obtain the final conjugate (Scheme 1) [32] . The excess NiCl 2 was removed using a Zeba desalting column and the purified conjugate was analyzed by inductively coupled mass spectrometry (ICP-MS) analysis to quantify the amount of Ni chelated to the NTA head group of the Brij 700-NTA conjugate. Results from ICP-MS analysis showed that the ratio of Brij 700-NTA to Ni was close to 1:1 after purification with a Zeba desalting column indicating near quantitative yields (Table 1) .
Optimization of BTM-Ni NPs formulation using Brij 700-NTA-Ni
The preparation of Ni-loaded BTM NPs (Ni-NPs) can be carried out in a number of ways, including (a) the use of the commercially available DOGS-NTA-Ni conjugate which can be incorporated into the lipid core of the BTM NPs, (b) the use of Brij 700-NTA-Ni synthesized from Brij 700 previously added as a pegylation agent for the original BTM NPs formulation, and (c) the use of Brij 78-NTA-Ni synthesized from Brij 78, the main surfactant component in the BTM NP formulation. Previous studies in our lab showed that the use of DOGS-NTA-Ni to incorporate Ni in lipid-based NPs resulted in very little Ni incorporation (b10%) [28] . This is thought to be due to the hydrophobic nature of DOGS-NTA, which presumably incorporates within the NPs but limits accessibility of Ni to the surface of the NPs. This limitation can be addressed by conjugating the NTA-Ni head group to a molecule that would have both a hydrophilic chain to promote accessibility of Ni to the surface of the NPs, and a hydrophobic chain that would enhance incorporation of the conjugate within the lipid core of the NPs.
To do this, a novel Brij 700-NTA-Ni conjugate was successfully synthesized using Brij 700. When Brij 700 was added as a PEGylating agent in the BTM NP formulation, the optimal amount was determined at 8% w/w (Brij 700 to Miglyol 812) [33] . Based on these findings, optimization of the new BTM-Ni NP formulation was carried out using various amounts of Brij 700-NTA-Ni conjugate ranging from 0.5 to 8% w/w (Brij 700-NTA-Ni to total NP) ( Table 2 ). The Ni-NPs were characterized by measuring their particle size and zeta potential, and by ICP-MS analysis to quantify the percent Ni associated with each NP composition. The Ni-NPs had a mean size of~190 nm and exhibited an increasing negative charge with increasing Ni content ranging from − 12 mV to − 22 mV (Table 3 ).
Incorporation efficiency of Brij 700-NTA-Ni in NPs based on Ni content
The concentration of Ni in the various NP formulations was quantified by ICP-MS analysis. Prior to analysis, the Ni-NPs were purified by size exclusion chromatography (SEC) using a Sepharose CL-4B packed column to isolate NPs within the 200 nm range. Both unpurified and purified Ni-NPs were transferred to individual 15 mL Falcon tubes and diluted with 2% nitric acid (10 mL) for analysis. The percent Ni incorporation in the purified Ni-NPs was calculated in reference to the original Ni concentrations of the unpurified Ni-NPs. ICP-MS analysis showed a significant increase in Ni incorporation within the NPs (32-48%, Table 4 ) compared to much lower incorporation efficiency (6-7%) previously obtained with DOGS-NTA-Ni [34] . Results also indicated that increasing Brij 700-NTA-Ni content beyond 2% w/w did not seem to further increase the incorporation efficiency of Ni within the NPs. This is likely due to an equilibrium factor between Brij 78 and Brij 700-NTA-Ni since the original amount of Brij 78 was reduced accordingly to compensate for the addition of Brij 700-NTA-Ni and keep the total amount of surfactants constant in the NP formulation (Table 2) . Consequently, beyond a certain percent of Brij 700-NTANi, a saturation point is reached, which makes incorporation within the NPs more difficult, resulting in a plateau at~50% Ni incorporation (Table 4) . However, the main goal of the present work was to design a system with a high Ni content but also with an incorporation efficiency that was close to quantitative in order to avoid extra purification steps to remove free NTA-Ni conjugate. 
Binding efficiency of his × 6-tagged GFP to the Ni-NPs
Based on the promising Ni incorporation results obtained with Brij 700-NTA-Ni, further work to evaluate binding efficiency of the Ni-NPs to his × 6-tagged proteins was carried out using his × 6-tagged GFP as a model protein. The Ni-NPs were incubated with his × 6-tagged GFP at a previously optimized ratio (data not shown) of 0.0045 w/w his-GFP to NPs at 4°C overnight. SEC was used to separate unbound his × 6-tagged GFP, and fractions (1 mL) 1-24 were collected and analyzed by fluorescence spectroscopy to determine the amount of fluorescence associated with the NPs fractions (4-7). The binding efficiency of his × 6-tagged GFP to the Ni-NPs was~55% based on the percent fluorescence associated with the NPs fractions (~2.46 μg GFP/mg NPs). Surprisingly, these values were comparable to the binding efficiency of his-GFP to Ni-NPs prepared with DOGS-NTA-Ni (~48%, 2.19 μg GFP/mg NPs) ( Table 5 ). Given the 8-fold increase in Ni incorporation using Brij 700-NTA-Ni, these results suggested that the binding efficiency of his × 6-tagged GFP to Ni-NPs was not proportional to the amount of Ni within the NPs alone. It was hypothesized that, the low binding efficiency of his × 6-tagged GFP to the Ni-NPs was due to two reasons: 1) high chain dynamics and mobility in water of the long PEG chain (PEG MW = 4 kDa, Brij 700-NTA-Ni) induced protein repulsion [35, 36] , therefore hindering his-GFP binding to the Ni-NPs, 2) an equilibrium phenomenon, which favors Brij 700-NTA-Ni to be in the aqueous environment surrounding the NPs rather than its incorporation within the lypophilic core of the NPs. To test these hypotheses, an intermediate conjugate between the fully lypophilic DOGS-NTA-Ni and Brij 700-NTA-Ni with the long PEG chain was synthesized. This was accomplished using polyoxyl 20-stearyl ether (Brij 78) (MW = 1152 Da), the main surfactant in the BTM NP formulation, which differs from Brij 700 only in the length of the PEG chain (Mw = 4400 Da for Brij 700 versus Mw = 880 Da for Brij 78).
Optimization of Ni-NP formulation for binding to his × 6-tagged GFP using Brij 78-NTA-Ni
Synthesis of Brij 78-NTA-Ni was carried out following the same synthetic steps used to make Brij 700-NTA-Ni conjugate (Scheme 1). In this new formulation, 50 wt.% of Brij 78 in the original BTM NP formulation [37] was substituted with Brij 78-NTA-Ni. The percent incorporation of Ni using Brij 78-NTA-Ni was significantly higher, where 89% of the original Ni amount was associated with the NPs fraction as determined by ICP-MS analysis ( Table 5 ). The structural similarity of Brij 78-NTA-Ni and Brij 78, the main surfactant in the NPs formulation, allowed incorporation of greater amounts (up to 80 wt.%) of Brij 78-NTA-Ni in the NPs formulation resulting in enhanced Ni incorporation. This was not the case with Brij 700-NTANi, where the optimal amount that could be added to the NPs formulation was 8 wt.%. These results were extremely promising in that being able to achieve nearly quantitative Ni incorporation with Brij 78-NTA-Ni allowed for the development of a formulation that can readily be used for in vitro and in vivo studies. Moreover, when increasing the amount of Brij 78-NTA-Ni to 80% w/w (Brij 78-NTA-Ni to Brij 78), there was no significant enhancement in the percent Ni incorporation (90%) within the NPs. This suggested that increasing the amount of Brij 78-NTA-Ni beyond 50% w/w did not further enhance percent Ni incorporation within the NPs.
Binding studies of his × 6-tagged GFP to this new Ni-NPs formulation were carried out using the aforementioned optimal binding conditions (0.0045 w/w his × 6-tagged GFP to Ni-NPs). Fluorescence analysis of SEC fractions showed a significant enhancement in binding efficiency (~85%, 3.83 μg GFP/mg NPs) compared to previous results obtained with Brij 700-NTA-Ni based NPs (~55%,~2.46 μg GFP/ mg NPs) ( Table 5 ). These results support our hypothesis that by shortening the length of the PEG segment on the NTA-Ni conjugate, enhanced Ni incorporation and binding efficiencies to a his × 6-tagged protein were observed. Based on these results, optimization studies for binding of a novel his × 6-tagged heptameric Z EGFR domain to the new Ni-NPs to target them to EGFR-overexpressing cancer cells were carried out.
Optimization of FITC-labeled his × 6-tagged heptameric Z EGFR domain binding to the Ni-NPs
One of the main limitations of coupling proteins to carriers using a noncovalent his-tag-Ni interaction is the potential disruption of the his-Ni-NTA association in vivo. Szoka et al. showed that while increasing the retention of his × 6-tagged proteins to multivalent NTA headgroups in vitro, this association was not robust enough in vivo [38] . In the present work, we investigated the potential improvement of the his-tag-Ni-NTA association in vivo using a multi-his × 6-tagged protein (heptameric Z EGFR domain) to bind to a NP system that exhibits high Ni content and improved Ni accessibility to the his × 6-tagged protein.
The high affinity (K d = 29 pM) heptameric Z EGFR domain was prepared by fusing a heptamerization domain with an EGFR-binding Z domain. This process allowed for the formation of a highly stable heptameric structure, without formation of other multimeric intermediates. The targeting ligand was terminated with a his × 6-tag to allow for site-specific attachment to Ni-NPs via Ni-his-tag affinity binding. Binding studies were accomplished using FITC-labeled heptameric Z EGFR domain (FITC-his × 6-tagged heptamer) at various FITC-his-heptamer to Ni-NPs w/w ratios to determine the optimal conditions. SEC followed by fluorescence analysis showed that a binding ratio of 0.002 w/w (his × 6-tagged-heptamer to Ni-NPs) or lower yielded binding efficiencies > 90% (Fig. 1 , Table 6 , bold entry). These optimization studies were particularly important in minimizing purification steps required to separate unbound protein from NP-bound protein prior to in vitro and in vivo studies. Based on these results, in vitro and in vivo studies were completed with the optimal binding conditions of 0.002 w/w his × 6-tagged-heptamer to Ni-NPs ratio.
Facilitated in vitro cell uptake of EGFR-targeted Ni-NPs in EGFR+ cancer cells
In vitro cell uptake studies were carried out to determine the percent internalization of the targeted Ni-NPs in EGFR overexpressing epidermoid carcinoma cells, A431. Dose and time dependency of cell uptake were investigated at Ni-NPs concentrations of 1, 5 and 15 μg/mL and three time points (15 min, 1 h and 4 h). Cell uptake was quantified by flow cytometry analysis using a trypan blue (TB) assay that is based on the observation that the vital dye TB, while quenching the FITC fluorescence of non-internalized particles causing them to fluoresce red, induces internalized particles to fluoresce green [30] . Flow cytometry data showed up to 90% internalization of the EGFR-targeted Ni-NPs in the A431 cells with the highest concentration of NPs (15 μg/mL) and longest incubation time (4 h) ( Fig. 2A) . ICP-MS analysis, used to quantify cell-internalized Ni, was in good agreement with flow cytometry results showing a dose dependent increase in Ni internalization in A431 cells (Fig. 2B) .
Cell uptake competition studies were also carried out by first incubating the cells with free unlabeled heptameric Z EGFR domain for 30 min at various concentrations ranging from 0.035 ng/mL to 3.5 μg/ mL and then adding EGFR-targeted Ni-NPs (15 μg/mL) and incubating for an additional 4 h. The percent internalization of the targeted NiNPs in the A431 cells was competed off with free heptameric Z EGFR domain concentrations of 8.75 ng/mL or higher (Fig. 3A) . It is also noteworthy that the concentration of heptameric Z EGFR domain present in the targeted Ni-NPs when incubated at 15 μg/mL was 35 ng/mL. Interestingly, the competition studies showed that the most significant decrease in cell internalization of the targeted Ni-NPs occurred when the concentration of the free heptameric Z EGFR domain exceeded 35 ng/mL (Fig. 3A) . As shown in Fig. 3B , it was also demonstrated that increasing the heptameric Z EGFR domain concentration on the surface of the Ni-NPs, significantly enhanced the uptake of the NPs in EGFRoverexpressing A431 cells (as measured by cell internalized Ni using ICP-MS analysis). All together, these in vitro results were very encouraging in that they demonstrated superior cell uptake could be achieved in EGFR overexpressing cells with these Ni-NPs when targeted with the novel heptameric Z EGFR domain.
Facilitated in vivo accumulation of EGFR-targeted Ni-NPs in EGFR + cancer cells
Based on the results obtained from the in vitro studies, a preliminary in vivo study was carried out to test the efficacy of the novel heptameric Z EGFR domain in targeting the new Ni-NPs. The in vivo study was performed in female nude athymic (nu/nu) mice bearing A431 tumors to determine the biodistribution and intracellular delivery of the EGFR-targeted Ni-NPs. IVIS fluorescence imaging (to detect Alexa750-labeled heptameric Z EGFR domain) and ICP-MS (to detect Ni) were both utilized to monitor untargeted and targeted Ni-NPs.
Whole-body fluorescence imaging demonstrated visible tumor accumulation of the targeted Ni-NPs with no accumulation in the heart, lungs, stomach, intestines, or spleen (Fig. 4) . Using the same female nude athymic (nu/nu) mice, qualitative biodistribution data were collected by harvesting the organs and tissues at 16 h post injection of untargeted and targeted Ni-NPs via tail vein. The organs and tissues harvested from each mouse included blood (via heart puncture), tumors, heart, lung, liver, kidneys, intestines, spleen and bladder. Semiquantitative information was obtained by defining regions of interest (ROIs) on the images and determining the number of counts in that volume. Fig. 5A depicts the relative fluorescence intensity measured, normalized to the point of maximum intensity. These results were in agreement with the whole-body images showing modest accumulation in the liver and a stronger signal in the kidneys, presumably due to heptameric Z EGFR domain elimination. The fluorescence intensity for EGFR-targeted Ni-NPs in the tumors was 19% of the total detected fluorescence intensity (FI). An additional 28% FI was detected in the liver and 42% FI was detected in the kidneys (Table 7) . In parallel to the fluorescence imaging studies, Ni accumulation in the tumor cells was quantified by ICP-MS analysis. Tumors were harvested 16 h post i.v. injection, and tumor cells were extracted from the tumor homogenates and analyzed for intracellular Ni accumulation. A significant enhancement of intracellular Ni accumulation was detected for the targeted Ni-NPs (Fig. 5B) . The percent intracellular Ni accumulation was 8% of the total injected dose (ID) of Ni, almost a two-fold increase from untargeted Ni-NPs (5%). Collectively, these new preliminary data were very promising and support the development of the novel heptameric Z EGFR domain to target EGFR overexpressing cancer cells.
Conclusions
The synthesis of two new NTA-Ni conjugates was successfully accomplished with both Brij 700 and Brij 78. Using these new conjugates, Ni-NPs with high Ni incorporation (~50% and~90% respectively) and facilitated Ni access to the surface of the NPs were prepared. Combined, these two advantages resulted in enhanced binding efficiencies of his × 6-tagged GFP to the Ni-NPs. Interestingly, higher binding efficiencies to his × 6-tagged GFP were observed for Ni-NPs prepared with Brij 78-NTA-Ni conjugate (85% vs. 55%). These results suggested that conjugating the NTA-Ni group to a shorter PEG chain (Brij 78 vs. Brij 700) promoted greater protein binding via his-tag-Ni affinity interaction. The new Ni-NPs (80% w/w Brij 78-NTA-Ni) were decorated with a novel his × 6-tagged heptameric Z EGFR domain with up to 95% binding efficiency at optimal conditions (0.002 w/w Z EGFR domain to Ni-NPs). In vitro cell uptake studies showed up to 90% internalization of the EGFR-targeted Ni-NPs into the EGFR overexpressing A431 cells, as compared to significantly lower uptake (b10%) of the untargeted Ni-NPs. The targeting efficiency of the novel heptameric Z EGFR domain was also demonstrated in vivo with almost a two-fold increase in intracellular Ni accumulation in tumor homogenates. To our knowledge, this is the first report on the use of a novel heptameric Z EGFR domain to successfully target EGFR overexpressing cancer cells and the data support the development of the novel heptameric Z EGFR domain to target EGFR overexpressing cancer cells.
Future studies will focus on translating the use of the novel heptameric Z EGFR domain to target drug-loaded NPs to EGFR overexpressing breast cancer cells (MDA-MB-468) and EGFR overexpressing nonsmall cell lung cancer cells (A549).
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